In this era of reform and value-based care, where defining and messaging your value proposition and facilitating successful market access are keys to growth, life sciences companies are challenged to continually innovate and meet changing customer needs.

Our life sciences team has worked with medical device, biotech and pharmaceutical companies to address such business challenges as market access and commercialization, ongoing capital requirements, health economic value analysis and evaluation of exit strategies. Baker Tilly’s team provides you with actionable ideas and solutions, including peer-reviewed health economic studies, drawn from our work with hundreds of life sciences companies. 

  • Transition to ASC 606 with application of new accounting guidance
  • Provide insights regarding implementation of value based care initiatives
  • Fuel growth by harnessing valuable sources of structured and unstructured data
  • Help ensure compliance with applicable HIPAA requirements
  • Assist in complying with federal and state tax requirements, including state nexus rules
  • Analyze and apply for research and development tax credits
  • Protect your assets from cyber threats
  • Leverage opportunities in the international marketplace
  • Assist with your financing needs, including a public offering

We work with privately held and public companies and private equity firms and their portfolio companies through all stages of the life sciences life cycle – from launch to growth to maturity to exit.

If you want a team that understands your industry, gets to know your business intimately and offers profitable solutions while minimizing risk, connect with us.

Surfacing Value from Unstructured Patient Data

Surfacing Value from Unstructured Patient Data

Mining unstructured data can have tremendous business impact in any industry; however, some have more to gain than others. In the health and life sciences sector there is a tremendous opportunity to transform organizational practices by enabling the analysis of unstructured data sourced from publicly available discussion forum websites. In this LinkedIn post, Andrew Malinow, Baker Tilly' s Director of Business Analytics, discusses how an analytics platform can be used to glean insights from unstructured primary patient data.

Learn more >
Implications of revenue recognition standard for life sciences companies

Implications of revenue recognition standard for life sciences companies

For life sciences companies, the new revenue model may have the greatest impact on collaboration and licensing arrangements. For some medical device manufacturers, reseller and distributor arrangements may also be impacted.

Learn more >

Our Take

image of Mike D. McKee

“Our team’s experience serving life sciences companies helps you balance innovation, productivity and risk. We can help you stay ahead of industry changes and opportunities throughout your company’s lifecycle.”

— Mike D. McKee Partner, CPA